INDOCO REMEDIES
|
|
BOM : 532612     NSE : INDOCO     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Dec 05,2024 |
Price(EOD): ₹ 320.50
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 2,955.01 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
INDOCO REMEDIES | 2.3% | 2.5% | -11.4% |
SUN PHARMACEUTICAL INDUSTRIES | 3.7% | -3.2% | 46.6% |
CIPLA | 0.6% | -3.7% | 26.7% |
DR REDDYS LABORATORIES | 1.9% | -3.4% | 5.8% |
ZYDUS LIFESCIENCES | 2.3% | -3.4% | 54% |
DIVIS LABORATORIES | 5.1% | 6.1% | 64% |
MANKIND PHARMA | 1.3% | -3.5% | 35.8% |
TORRENT PHARMACEUTICALS | 4.6% | 4.4% | 58% |
LUPIN | 5.1% | -4.4% | 62.5% |
FUNDAMENTAL ANALYSIS OF INDOCO REMEDIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF INDOCO REMEDIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
100.49
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 29.40 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 2.67
P/B Calculated based on Book Value of Rs 1,106.36 Cr
[Latest Year - Mar2024 - Consolidated Results ] 1.67
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,773.21 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-31% -21% -17% |
SHARE PRICE MOMENTUM OF INDOCO REMEDIES
INDOCO REMEDIES vs SENSEX
DEBT OF INDOCO REMEDIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.44 0.31 0.27 0.34 |
0.59 0.31 0.27 0.39 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF INDOCO REMEDIES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF INDOCO REMEDIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
0.27% -15.74% -169.44% -650% |
-10.19% -43.6% -110.46% -128.41% |
QtrlyTrend |
-6 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
INDOCO REMEDIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 4.1% | 1% | 46.7% |
S&P BSE SMALL CAP | 3.5% | 2% | 40.5% |
S&P BSE MIDSMALLCAP | 3.4% | 3% | 40.6% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
You may also like the below Video Courses
FAQ about INDOCO REMEDIES
Is INDOCO REMEDIES good for long term investment?
As on Dec 05,2024, the Fundamentals of INDOCO REMEDIES look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of INDOCO REMEDIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is INDOCO REMEDIES UnderValued or OverValued?
As on Dec 05,2024, INDOCO REMEDIES is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of INDOCO REMEDIES ?
As on Dec 05,2024, the Intrinsic Value of INDOCO REMEDIES is Rs. 404.42 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 463.56
Fair Value [Median EV / Sales Model] : Rs. 404.42
Fair Value [Median Price / Sales Model] : Rs. 384.06
Estimated Median Fair Value of INDOCO REMEDIES : Rs. 404.42
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.